Cargando…
MicroRNAs in melanoma development and resistance to target therapy
microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5′ end of a 21-23 nt...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400662/ https://www.ncbi.nlm.nih.gov/pubmed/28118616 http://dx.doi.org/10.18632/oncotarget.14763 |
_version_ | 1783230897175134208 |
---|---|
author | Fattore, Luigi Costantini, Susan Malpicci, Debora Ruggiero, Ciro Francesco Ascierto, Paolo Antonio Croce, Carlo M. Mancini, Rita Ciliberto, Gennaro |
author_facet | Fattore, Luigi Costantini, Susan Malpicci, Debora Ruggiero, Ciro Francesco Ascierto, Paolo Antonio Croce, Carlo M. Mancini, Rita Ciliberto, Gennaro |
author_sort | Fattore, Luigi |
collection | PubMed |
description | microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5′ end of a 21-23 nt sequence with a partially complementary sequence located in the 3′ untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors. |
format | Online Article Text |
id | pubmed-5400662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54006622017-05-03 MicroRNAs in melanoma development and resistance to target therapy Fattore, Luigi Costantini, Susan Malpicci, Debora Ruggiero, Ciro Francesco Ascierto, Paolo Antonio Croce, Carlo M. Mancini, Rita Ciliberto, Gennaro Oncotarget Review microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5′ end of a 21-23 nt sequence with a partially complementary sequence located in the 3′ untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors. Impact Journals LLC 2017-01-19 /pmc/articles/PMC5400662/ /pubmed/28118616 http://dx.doi.org/10.18632/oncotarget.14763 Text en Copyright: © 2017 Fattore et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Review Fattore, Luigi Costantini, Susan Malpicci, Debora Ruggiero, Ciro Francesco Ascierto, Paolo Antonio Croce, Carlo M. Mancini, Rita Ciliberto, Gennaro MicroRNAs in melanoma development and resistance to target therapy |
title | MicroRNAs in melanoma development and resistance to target therapy |
title_full | MicroRNAs in melanoma development and resistance to target therapy |
title_fullStr | MicroRNAs in melanoma development and resistance to target therapy |
title_full_unstemmed | MicroRNAs in melanoma development and resistance to target therapy |
title_short | MicroRNAs in melanoma development and resistance to target therapy |
title_sort | micrornas in melanoma development and resistance to target therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400662/ https://www.ncbi.nlm.nih.gov/pubmed/28118616 http://dx.doi.org/10.18632/oncotarget.14763 |
work_keys_str_mv | AT fattoreluigi micrornasinmelanomadevelopmentandresistancetotargettherapy AT costantinisusan micrornasinmelanomadevelopmentandresistancetotargettherapy AT malpiccidebora micrornasinmelanomadevelopmentandresistancetotargettherapy AT ruggierocirofrancesco micrornasinmelanomadevelopmentandresistancetotargettherapy AT asciertopaoloantonio micrornasinmelanomadevelopmentandresistancetotargettherapy AT crocecarlom micrornasinmelanomadevelopmentandresistancetotargettherapy AT mancinirita micrornasinmelanomadevelopmentandresistancetotargettherapy AT cilibertogennaro micrornasinmelanomadevelopmentandresistancetotargettherapy |